VRCA (Verrica Pharmaceuticals) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRCA Verrica Pharmaceuticals Inc VRCA
47 GF Score
Price $4.49
GF Value $8.34
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Verrica Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Verrica Pharmaceuticals  (NAS:VRCA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Verrica Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Verrica Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Verrica Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verrica Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Verrica Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 2.95

Verrica Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 2.95 1.84 2.11

VRCA vs RANI, CGTX, KLRS: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Verrica Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verrica Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Verrica Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


VRCA
47GF Score
Verrica Pharmaceuticals Inc VRCA
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Verrica Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Verrica Pharmaceuticals's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Verrica Pharmaceuticals's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=3.34/324.0540*324.0540
=3.340

Current CPI (Dec25) = 324.0540.

Verrica Pharmaceuticals Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 0.000 241.432 0.000
201712 0.000 246.524 0.000
201812 0.000 251.233 0.000
201912 0.000 256.974 0.000
202012 0.000 260.474 0.000
202112 4.437 278.802 5.157
202212 2.644 296.797 2.887
202312 1.130 306.746 1.194
202412 1.460 315.605 1.499
202512 3.340 324.054 3.340

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Verrica Pharmaceuticals (VRCA) Overvalued in 2026?

Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued. The current stock price of $4.49 is trading 46.2% below its estimated GF Value™ of $8.34. GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.

Key valuation signals for VRCA:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $8.34 vs. price of $4.49 (46.2% below fair value)
  • GF Score™: 47/100 with 1 warning sign

No single metric tells the full story. See the VRCA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Verrica Pharmaceuticals Business Description

Other Exchanges 1NE0:Germany
Address 44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
47GF Score

Get the complete analysis for VRCA

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.49
Price
$8.34
GF Value